Ipamorelin Peptide: What Is It Studied For?

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue, meaning it stimulates the release of growth hormone without significantly affecting other pituitary hormones. Its amino acid sequence — Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — was identified through an extensive medicinal chemistry program, as described in a 1998 preclinical study published in the European Journal of Endocrinology. That same research characterized it as distinct from earlier secretagogues by virtue of its selectivity: unlike GHRP-6 and related compounds, it does not produce meaningful elevations in cortisol, prolactin, or ACTH at effective doses in animal models. It acts as an agonist at the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous peptide ghrelin.

---

What Is Ipamorelin Studied For?

Research on Ipamorelin goes back to 1998 — nearly 30 years — with studies continuing through 2024.

1. Growth Hormone Release and Selectivity — A 1998 rat preclinical study published in the European Journal of Endocrinology reported that Ipamorelin produced potent, dose-dependent GH release both in vitro and in vivo, while demonstrating significantly greater selectivity compared to GHRP-2 and GHRP-6, which triggered broader hormonal responses.

2. Longitudinal Bone Growth — A 1999 rat preclinical study found that subcutaneous administration three times daily over 15 days increased longitudinal bone growth rate in adult female rats in a dose-dependent manner, alongside increases in body weight and GH pulse amplitude.

3. Gastrointestinal Motility After Surgery — A 2009 rodent study in The Journal of Pharmacology and Experimental Therapeutics reported that Ipamorelin accelerated gastrointestinal transit and reduced the duration of postoperative ileus symptoms following laparotomy and intestinal manipulation in male rats.

4. Cisplatin-Induced Weight Loss — A 2024 ferret preclinical study in Physiology & Behavior found that Ipamorelin inhibited weight loss and suppression of food intake during both acute and delayed phases of cisplatin-induced emesis, though it did not demonstrate the anti-emetic effect seen with the comparator compound anamorelin.

5. Detection in Human Doping Contexts — A 2018 human-observational analysis identified Ipamorelin in black-market products seized through sports drug testing; this work documented the compound's real-world presence in performance contexts rather than evaluating efficacy, and no sample size for human subjects was reported.

---

How Does Ipamorelin Work?

Ipamorelin binds selectively to the GHS-R1a receptor — the ghrelin receptor — expressed in the pituitary gland and hypothalamus. A 1998 preclinical study in the European Journal of Endocrinology described how this binding triggers GH release through a mechanism distinct from growth hormone-releasing hormone (GHRH), meaning the two can produce additive effects when combined in animal models. Critically, the same study reported that Ipamorelin did not stimulate significant release of adrenocorticotropic hormone (ACTH), cortisol, or prolactin at doses that produced robust GH secretion — a selectivity profile that separates it from older secretagogues like GHRP-6.

A 2003 preclinical study in Histology and Histopathology examined what happens to pituitary somatotroph cells under chronic treatment in young female rats. It found changes in the composition of the somatotroph cell population and in in-vitro GH secretory responses, suggesting that sustained GHS-R1a stimulation produces adaptive changes at the cellular level rather than a static, unchanging response over time.

Downstream from GH release, the compound's effects on ghrelin receptor signaling also appear relevant to gastrointestinal function. A 2009 rodent preclinical study found that GHS-R1a agonism enhanced gastric motility and accelerated intestinal transit, consistent with the known role of ghrelin in gut physiology.

---

What Does Animal Research Show?

The majority of published Ipamorelin research has been conducted in rodent and ferret models, and the findings span several physiological systems.

Bone growth: A 1999 rat study published in Growth Hormone & IGF Research administered Ipamorelin subcutaneously at escalating doses over 15 days to adult female rats. Intravital tetracycline labeling was used to measure longitudinal bone growth rate directly. The data showed a dose-dependent increase in growth rate alongside elevated GH pulse amplitude — a result that linked the compound's GH-releasing activity to a measurable skeletal outcome in that model, though findings are limited to adult female rats under short-term dosing conditions.

Pharmacokinetics: A 1999 study in Xenobiotica compared the pharmacokinetics of Ipamorelin against GHRP-2, GHRP-6, and two other secretagogues in male rats using intravenous, subcutaneous, and intranasal routes. Plasma concentrations following intravenous bolus declined biexponentially, and Ipamorelin's pharmacokinetic profile differed meaningfully from the hexapeptide comparators. Nasal bioavailability was evaluated as part of assessing non-injectable administration routes, though the study's primary focus was comparative kinetics rather than efficacy.

Pituitary adaptation: The 2003 preclinical study in young female rats treated chronically with Ipamorelin documented changes in somatotroph cell population composition and altered in-vitro secretory responses. This indicated that the pituitary adapts under sustained GHS-R1a stimulation — a finding relevant to understanding the long-term biology of the compound, though it does not directly translate to human physiology without further study.

Postoperative ileus: A 2009 study in JPET used a well-characterized rat model of postoperative ileus (POI) involving laparotomy and intestinal manipulation in fasted male animals. Ipamorelin treatment accelerated gastrointestinal transit recovery and ameliorated functional symptoms of POI. The authors positioned this as a potential therapeutic angle for post-surgical GI dysfunction, though all findings remain within the rodent preclinical context.

Cisplatin-related weight loss: A 2024 ferret preclinical study in Physiology & Behavior investigated both Ipamorelin and the related compound anamorelin in a cisplatin-induced emesis model. Ipamorelin reduced weight loss and feeding suppression in the acute and delayed phases. However, when isolated ferret ileum preparations were tested, ipamorelin did not inhibit electrical field stimulation-induced contractions the way anamorelin did, indicating mechanistic differences between the two GHS-R1a agonists despite overlapping receptor targets.

Structural analogue development: A 1998 study in the Journal of Medicinal Chemistry described a series of new GH secretagogues derived from Ipamorelin's scaffold. Researchers applied backbone N-methylation and peptidomimetic strategies in an attempt to identify orally bioavailable analogues, with several showing high in-vitro potency. This work explored the compound as a structural template rather than characterizing Ipamorelin itself as a therapeutic candidate.

---

What Does Human Research Show?

Controlled clinical trial data on Ipamorelin is absent from the current published literature. The only human-contextual evidence in the primary study pool is an observational analysis published in 2018 in Growth Hormone & IGF Research.

That analysis examined black-market products submitted through sports drug-testing channels. Ipamorelin was among the GH-releasing peptides detected and characterized. The study's authors — notably, two authors (Andersen P H and Johansen P B) appear across multiple studies in this field, and the journal Growth Hormone & IGF Research accounts for two of the eight primary studies reviewed — focused on analytical identification and anti-doping implications, not on pharmacological efficacy or safety outcomes in human subjects. No participant sample size was reported. This work documents the compound's presence in human performance contexts but provides no evidence for or against efficacy or safety in people.

The gap between the rodent and ferret preclinical data and any confirmed human pharmacodynamic profile remains an open research question.

---

What Is Still Unknown About Ipamorelin?

Several areas remain unresolved. No published randomized controlled trials or even open-label safety pilots in human subjects appear in the primary literature. The bone growth findings from the 1999 rat study, while mechanistically plausible, have not been replicated in human models. Similarly, the postoperative ileus data from rodents — despite representing a clinically meaningful potential application — has not advanced to a known human trial.

The 2003 pituitary study raised questions about cellular adaptation under chronic treatment that have not been followed up in published human work. Whether the selectivity profile observed in rat models — specifically, the absence of cortisol and prolactin elevation — holds in humans across a range of doses and durations remains unconfirmed by any study in this pool.

The 2024 ferret study highlighted that two GHS-R1a agonists with overlapping receptor targets can produce different downstream effects depending on the tissue and assay context. This suggests that receptor selectivity alone does not fully predict physiological outcomes, and that Ipamorelin's effects in complex human physiology may diverge from what preclinical models indicate.

Research concentration also warrants transparency: two authors (Andersen P H and Johansen P B) appear across multiple primary studies, and much of the foundational characterization work originates from a narrow group of investigators publishing in the late 1990s. Independent replication in human populations has not been documented in this literature pool.

---

Where Can I Buy Ipamorelin?

Ipamorelin is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---